- Used in combination with AI like letrozole as first-line therapy for patients with metastatic, ER-positive breast cancer
- highly selective, oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6)
- Major side effects include neutropenia, fatigue, nausea, and alopecia
- administered in a 28 day cycle (21 days on, 1 week of rest for bone marrow recovery)
Posted 09/12/16 02:05:23 PM by Anna Krigel
- Neutropenia -> ANC < 1500 cells/microL (severe neutropenia -> ANC < 500 cells/microL)
- Calculate ANC by taking total WBC count and multiplying by percentage of PMNs and bands
- Initiate empiric antibiotic therapy according to the neutropenic fever guidelines immediately after blood cultures are obtained and before any other investigations are completed
Posted 09/12/16 02:51:52 PM by Anna Krigel
mTOR inhibition in LAM (lymphangioleiomyomatosis)
- sirolimus (Rapamycin) has been shown to slow disease progression in moderate-to-severe pulmonary LAM
- patients with LAM typically have mutations in the tumor suppressor gene encoding tuberin (TSC2), which normally inhibits mTOR activation
- sirolimus inhibits the mTOR complex
- has been associated with amelioration of pulmonary function tests, chylous effusions, and lymphangioleiomyomas
- also being used to treat PEComas
Posted 09/12/16 03:19:48 PM by Anna Krigel
For further reading...
Posted 09/12/16 03:39:59 PM by Anna Krigel
Created by Christopher Kelly
The information on the website does not constitute official guidelines except where explicitly stated.
It is not meant to replace the advice of a health professional.